Navigation Links
Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
Date:10/28/2009

cals, Shire. "We are firmly committed to serving the needs of renal patients and ensuring that FOSRENOL is available to the prescribers and patients who can benefit from it."

In relation to the US, Shire continues to evaluate its options for securing a label extension to include CKD patients not on dialysis.

    Notes to Editors

    ABOUT FOSRENOL(R) (lanthanum carbonate)

    FOSRENOL is indicated:

    - In the EU as a phosphate binding agent for use in the control of
      hyperphosphataemia in chronic renal failure patients on haemodialysis
      or continuous ambulatory peritoneal dialysis. FOSRENOL is also
      indicated in adult patients with chronic kidney disease not on dialysis
      with serum phosphate levels greater than or equal to 1.78 mmol/L in
      whom a low phosphate diet alone is insufficient to control serum
      phosphate levels.(1)

    - In the US to reduce serum phosphate in patients with end stage renal
      disease.(2)

    - FOSRENOL is not available in all countries and prescribing information
      may differ between countries. Please consult your local prescribing
      information.(2)

    - FOSRENOL works by binding to dietary phosphate in the GI tract; once
      bound, the lanthanum/phosphate complex cannot pass through the
      intestinal lining into the blood stream and is eliminated from the
      body.(1) As a consequence, overall phosphate absorption from the diet
      is decreased.

    - FOSRENOL is available in a broad range of dosage strengths including
      500mg, 750mg, and 1000mg tablets1 which facilitates an effective dosing
      regimen of one tablet per meal for the majority of patients.

    - FOSRENOL was first approved in Sweden in March 2004, and by the US FDA
      in October 2004. FOSRENOL was subsequently approved in all EU markets
      by the European Mutual Recognition Procedure and is now launched in 37
      markets worldwide. It continues to be approved and made availa
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
2. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
3. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
4. Shire Initiates Two Adult ADHD Outreach Programs
5. Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
6. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
7. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
8. Shire begins the year with a strong performance
9. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
10. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
11. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... GLASGOW, Scotland , September 17, 2014 ... a new mode of action from a ... a decade  MGB Biopharma, a ... of anti-infectives, announces today that it has ... of its lead antibacterial, MGB-BP-3, against a ...
(Date:9/16/2014)... Washington, USA (PRWEB) September 16, 2014 ... to create the features that we desire in optical ... Center at Montana State University. “As we explore surfaces ... Some of those lessons were presented in San Diego ... of Light: Light in Nature ” chaired by Shaw ...
(Date:9/16/2014)... 16, 2014 --The emerging field of molecular electronics ... next level, enabling the construction of tiny circuits ... individual molecules would take on the roles currently ... A team of researchers from five Japanese and ... use in small-scale electronics: a molecule called picene. ...
(Date:9/16/2014)... HILL, N.C. , Sept. 16, 2014 ... experimental heart failure compound has been shown to be ... preclinical results demonstrate an alternative to intravenous infusions that ... HNO prodrugs. The data were presented yesterday at the ... Annual Scientific Meeting in Las Vegas ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2
... DIEGO, April 15 Mr. Glynn has over 34 ... is well,known within the life sciences industry for his ... Most notably, Mr. Glynn,retired from Invitrogen Corporation (Nasdaq: ... company, he held several operating roles including CFO,President and ...
... NEW HAVEN, Conn., April 15 Vion,Pharmaceuticals, Inc. (Nasdaq: ... a,plan to achieve and sustain compliance with The Nasdaq ... of the plan., Previously, the Company announced that ... The Nasdaq Stock Market, Inc., notifying the Company,that it ...
... April 15 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) ... the,American Association for Cancer Research (AACR) in San Diego. ... of the HGF,receptor tyrosine kinase (MET), inhibits growth of ... the afternoon poster session,entitled Small Molecule Kinase Inhibitors 1 ...
Cached Biology Technology:eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008 2Vion Pharmaceuticals Files Plan With Nasdaq 2Vion Pharmaceuticals Files Plan With Nasdaq 3SGX Presents Preclinical MET Data at AACR 2SGX Presents Preclinical MET Data at AACR 3
(Date:9/17/2014)... Trees have been growing significantly faster since the 1960s. ... barely changed, but they have accelerated -- by as ... a study carried out by scientists from Technische Universitt ... that have been continuously observed since 1870. Their findings ... Three decades ago, "forest dieback" was a hot topic, ...
(Date:9/16/2014)... women in Australia is increased by lower socioeconomic ... September) in BJOG: An International Journal of ... high standards of living; however, existing research has ... indigenous and non indigenous Australians. , This case-control ... socioeconomic position on severe maternal morbidities associated with ...
(Date:9/16/2014)... taught us that we inherit certain traits from our ... change how these genes play out by taking certain ... That,s exactly what a team of researchers at the ... their research of epigenetics research. , Epigenetics regulates ... DNA and histone proteins, which prevent permanent mutations or ...
Breaking Biology News(10 mins):Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... MCLEAN, Va., Nov. 29, 2012  Northrop Grumman Corporation (NYSE: ... proof of concept for an automated biometric information system ... will be operated for a trial period to enable ... enabled intelligence and to help determine the requirements for ...
... William Cooke, a professor in the UTSA College of Education ... selected to serve as the speaker of the Texas Chapter ... Tour. Over the course of a week, Cooke will deliver ... of ACSM,s Texas Chapter. "This is a big honor ...
... For the first time in its history, the American Society ... opening session of the ASCB,s Annual Meeting, for "An Evening ... Francisco, on Saturday, Dec. 15. Members of the ... will receive complimentary registration to the ASCB keynote addresses ...
Cached Biology News:Northrop Grumman Delivers Australian Automated Biometric Information System Trial Proof of Concept 2UTSA physiologist William Cooke named 2013 Lecture Series Speaker by Texas Sports Medicine Chapter 2Public invited to 'An Evening of Science & Art' at ASCB Annual Meeting 2
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
SHEEP ANTI FLECAINIDE...
ANTI PIG LDH H4...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: